Rx List Price Inflation Penalty Endorsed By US HHS Secretary
Executive Summary
Senate Finance Committee’s approach to penalize companies for raising WAC list prices is not a ‘price control,’ but a reasonable approach to change the incentives that distort pricing in the supply chain, US HHS Secretary Alex Azar says.
You may also be interested in...
Coronavirus Knocks Drug Pricing Down – But Not Off – Political Priority List In US
When the top US health official testified before Congress on the budget this past week, drug pricing was barely discussed. What a difference two weeks – and global spread of a novel infectious disease – makes.
Trump Administration Signals Deference To Congress On Drug Pricing Policy
In a marked departure from previous years, budget proposal offers few specifics on cost reductions, but the $135bn savings estimate is a tacit endorsement of the Grassley-Wyden bill in the Senate.
Point-Of-Sale Rebates May Be Added To US Senate Finance Drug Pricing Bill
Legislation clears committee with no major changes. However, the number of Republicans opposing the bill due to concerns over price inflation rebates portend difficulties ahead for a floor vote.